Strategic regeneration: Leveraging precision biologics and scalable innovation to transform spinal fusion
Bone Biologics (Nasdaq: BBLG) is a clinical-stage company developing differentiated regenerative medicine therapies for bone, primarily targeting the $3.0 billion spinal fusion market. Their lead product, NB-1, utilizes a proprietary recombinant protein called NELL-1 that is designed to act later in the bone formation pathway to support targeted bone growth with an advantageous safety profile. This … Read more